29 results
Thumbnail

- D3.223 - Investigating Allergens in Mandarin Seeds: A Case Study on Food-Induced Anaphylaxis

Thumbnail

- D3.224 - Barley Flour as a Major Allergen in Gluten-Induced Food Allergy

Thumbnail

- D3.226 - Unveiling Allergenic Variability in Peach: A Case Study of Profilin Sensitization and Cross-Reactivity

Thumbnail

- D3.230 - Thaumatin-like Protein (TLP) as a Common Allergen in Banana, Kiwi, Grape, and Avocado Allergy: A Case Study

Thumbnail

- D3.232 - Hidden allergy: Anaphylaxis despite negative initial tests

Thumbnail

D3.225 - Cysteine Protease Fic c 2 in Fig-Induced Allergy: A Case Study on Cross-Reactivity

Thumbnail

D3.227 - Millet as a Rare Allergenic Source: A Case Study of Systemic Allergic Reactions

Thumbnail

D3.228 - Distinguishing True Fish Roe Allergy from Contamination: A Case of Anaphylaxis Linked to Anisakis simplex

Thumbnail

D3.229 - Profiling Allergens in Onion and Garlic Shoots: A Case Study on Severe Food Allergy

Thumbnail

D3.231 - "All-You-Can-Eat": Omalizumab as a Curative Treatment for Severe Food Allergies - A Case Report

Thumbnail

D3.233 - DEFASE assessment for severity of wheat allergy in Chinese children

Thumbnail

D3.234 - Personalized Selection of Milk Formulas for Children with Cow’s Milk Allergy and Histamine Intolerance: Intersection of Innovative Allergy Management and Sustainability

Thumbnail

D3.235 - A Combined SLIT and OIT Approach for Desensitization in LTP Syndrome: A Promising Strategy

Thumbnail

D3.237 - Legumes Sensitization in Tree nut- vs. Peanut-Allergic Children: What Makes the Difference?

Thumbnail

D3.419 - Prevalence of physical urticaria hives in patients with systemic mastocytosis and their relation to disease course – preliminary data

Thumbnail

D3.411 - Targeting MRGPRX2 for the Treatment of Mast Cell-Driven Diseases

Thumbnail

D3.412 - MRGPRX2 Specific Activation Signature is Enriched in Atopic Dermatitis Lesions and Wheals from Chronic Spontaneous Urticaria Compared to Adjacent Healthy Skin

Thumbnail

D3.413 - Development of the Mastocytosis Symptom Severity Daily Diary (MS2D2) for Non-Advanced Systemic Mastocytosis (NonAdvSM) Patients and Establishing Content Validity

Thumbnail

D3.414 - The Phase 2/3 Study of Elenestinib, a Highly Potent and Selective Tyrosine Kinase Inhibitor, in Patients With Indolent Systemic Mastocytosis

Thumbnail

D3.415 - Clinical manifestations of Hereditary alpha-tryptasemia (HaT) in Patients with Mast Cell Activation Syndromes